Discovery of novel antimyeloma agents targeting TRIP13 by molecular modeling and bioassay.

ABSTRACT: Thyroid hormone receptor-interacting protein-13 (TRIP13) is an AAA⁺ ATPase that regulates protein complex assembly and disassembly and is known to be a chromosomal instability gene with the ability to repair DNA double-strand breaks. TRIP13 overexpression has been linked to the proliferation and development of many human malignancies, including multiple myeloma (MM). Accordingly, TRIP13 is recognized as a potential drug target for anticancer drug development. Although some TRIP13 inhibitors have been reported, none are under clinical trial or approved for clinical use. This study aimed to identify novel small molecules as potential TRIP13 inhibitors structurally different from previously reported compounds through molecular modeling and bioassays. As a result, five compounds wer

SUBMITTER: Bunu SJ 

PROVIDER: S-EPMC12053442 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature